Skip to main content
OpenTrials

Clinical trial condition

Relapsing-Remitting Multiple Sclerosis

Explore clinical trials studying Relapsing-Remitting Multiple Sclerosis. Study availability and eligibility vary by location and protocol.

98 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Relapsing-Remitting Multiple Sclerosis trial results

Completed

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Centennial, Colorado, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Lake Barrington, Illinois, United States
  • Research Site Lexington, Kentucky, United States
View all 19 locations
View Trial Details
Completed

Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis

NCT02090413

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Cork, Ireland
  • Research Site Dublin, Ireland
  • Research Site Dublin, Ireland
  • Research Site Dublin, Ireland
View all 21 locations
View Trial Details
Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

NCT01285401

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Vienna, Austria
  • Research Site Esbjerg, Denmark
  • Research Site Glostrup Municipality, Denmark
  • Research Site Sønderborg, Denmark
View all 38 locations
View Trial Details
Completed

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

NCT01310166

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Novartis Investigative Site Ostfildern, Baden-Wurttemberg, Germany
  • Novartis Investigative Site Altenholz-Stift, Germany
  • Novartis Investigative Site Andernach, Germany
  • Novartis Investigative Site Celle, Germany
View all 61 locations
View Trial Details
Completed

Dose-finding Study of MT-1303

NCT01742052

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brussels, Belgium
  • Research Site Sofia, Bulgaria
  • Research Site Edmonton, Canada
  • Research Site Zagreb, Croatia
View all 18 locations
View Trial Details
Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

NCT00870740

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Brno, Czechia
  • Research Site Hraddec Kralove, Czechia
  • Research Site Olomouc, Czechia
  • Research Site Pilsen, Czechia
View all 58 locations
View Trial Details
Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

NCT01064401

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Research Site Gilbert, Arizona, United States
  • Research Site Phoenix, Arizona, United States
  • Research Site Tucson, Arizona, United States
  • Research Site Little Rock, Arkansas, United States
View all 228 locations
View Trial Details

Related conditions